Literature DB >> 10389885

Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer.

K Ikeda1, Y Saeki, C Gonzalez-Agosti, V Ramesh, E A Chiocca.   

Abstract

OBJECT: The absence of in vitro models of neurofibromatosis Type 2 (NF2)-defective meningiomas has limited investigative efforts to study the biological effects of this gene in the pathogenesis of these tumors. The goals of this report are to show that gene transfer vectors can efficiently express the wild-type NF2 transgene into primary meningioma cells and to determine effects on cellular proliferation.
METHODS: In this study, the authors have compared the transducing capacities of a retrovirus, an adenovirus, and a herpes simplex virus amplicon vector for use in primary human meningioma cells harvested from human tumors excised from patients with and without NF2. Transduction efficiencies with the latter vector approached 100% and it was selected to transfer the wild-type NF2 transgene into these cells. Western blot analysis confirmed that vector-mediated gene transfer mediated the expression of the NF2-encoded polypeptide merlin. Overexpression of merlin significantly inhibited the proliferation of both NF2-negative and NF2-positive human meningioma cells when compared to the proliferation of cells transduced with a control vector.
CONCLUSIONS: This study demonstrates the feasibility of using vector-mediated gene transfer to study wild-type NF2 gene function in short-term cultures of primary human meningioma cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389885     DOI: 10.3171/jns.1999.91.1.0085

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  15 in total

1.  FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice.

Authors:  Shinichi Yoshimura; Tetsuyuki Teramoto; Michael J Whalen; Michael C Irizarry; Yasushi Takagi; Jianhua Qiu; Jun Harada; Christian Waeber; Xandra O Breakefield; Michael A Moskowitz
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

2.  Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression.

Authors:  Xun Zhang; Roger Gejman; Ali Mahta; Ying Zhong; Kimberley A Rice; Yunli Zhou; Pornsuk Cheunsuchon; David N Louis; Anne Klibanski
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

3.  FGF-2 regulation of neurogenesis in adult hippocampus after brain injury.

Authors:  S Yoshimura; Y Takagi; J Harada; T Teramoto; S S Thomas; C Waeber; J C Bakowska; X O Breakefield; M A Moskowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

Review 4.  Molecular pathogenesis of meningiomas.

Authors:  Arie Perry; David H Gutmann; Guido Reifenberger
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

Review 5.  Merlin: the wizard requires protein stability to function as a tumor suppressor.

Authors:  K Adam Morrow; Lalita A Shevde
Journal:  Biochim Biophys Acta       Date:  2012-06-30

6.  The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.

Authors:  Guang-Hui Xiao; Ryan Gallagher; Justin Shetler; Kristine Skele; Deborah A Altomare; Richard G Pestell; Suresh Jhanwar; Joseph R Testa
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

7.  Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter.

Authors:  S Prabhakar; G J Brenner; B Sung; S M Messerli; J Mao; M Sena-Esteves; A Stemmer-Rachamimov; B Tannous; X O Breakefield
Journal:  Cancer Gene Ther       Date:  2009-10-16       Impact factor: 5.987

8.  A genetic strategy to overcome the senescence of primary meningioma cell cultures.

Authors:  Gilson S Baia; Alison L Slocum; Jeanette D Hyer; Anjan Misra; Nouzhan Sehati; Scott R VandenBerg; Burt G Feuerstein; Dennis F Deen; Michael W McDermott; Anita Lal
Journal:  J Neurooncol       Date:  2006-03-23       Impact factor: 4.130

Review 9.  Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator.

Authors:  Sarah Beltrami; Richard Kim; Jennifer Gordon
Journal:  Anticancer Res       Date:  2013-01       Impact factor: 2.480

10.  Neurofibromatosis type 2 tumor suppressor protein, NF2, induces proteasome-mediated degradation of JC virus T-antigen in human glioblastoma.

Authors:  Sarah Beltrami; Emanuela Branchetti; Ilker K Sariyer; Jessica Otte; Michael Weaver; Jennifer Gordon
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.